AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19161949 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 50
Study 19161949 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 50
Study 17445650 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA fluorescence diagnosis (FD)
Number of subjects: 301
Study 17445650 — intervention group
Group type: COMPARATOR
Intervention: Conventional white light (WL)
Number of subjects: 301
Study 15625713 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 62
Study 15625713 — intervention group
Group type: COMPARATOR
Intervention: Health promotion intervention (Control)
Number of subjects: 62
Study 12154424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial blocker (BB) with single-lumen tube (SLT)
Number of subjects: 159
Study 12154424 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen tube (DLT)
Number of subjects: 159
Study 9495267 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 49
Study 9495267 — intervention group
Group type: COMPARATOR
Intervention: Control (antihypertensive drug treatment)
Number of subjects: 49
Study 9495267 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 7658498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (specific dosage and duration not mentioned)
Number of subjects: 9749
Study 29628151 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-1018
Number of subjects: 3
Study 29628151 — intervention group
Group type: COMPARATOR
Intervention: HBsAg-Eng
Number of subjects: 3
Study 28568112 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation (≤ 24 h) after superior cavopulmonary connection
Number of subjects: 390
Study 28568112 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 390
Study 28568112 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with early extubation
Number of subjects: 390
Study 28568112 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative analyses for early extubation
Number of subjects: 390
Study 28568112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for > 24 h
Number of subjects: 390
Study 26535958 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy (wCBT)
Number of subjects: 199
Study 26535958 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (ACG)
Number of subjects: 199
Study 23141637 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR knees during walking, stair ascent, and stair descent
Number of subjects: 90
Study 23141637 — intervention group
Group type: COMPARATOR
Intervention: Contralateral knees during walking, stair ascent, and stair descent
Number of subjects: 90
Study 23141637 — intervention group
Group type: COMPARATOR
Intervention: Healthy control knees during walking, stair ascent, and stair descent
Number of subjects: 90
Study 21199922 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 11
Study 21199922 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 11
Study 21199922 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 11
Study 19181729 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding groups intervention
Number of subjects: 18858
Study 19181729 — intervention group
Group type: COMPARATOR
Intervention: Control localities (no change in group activity)
Number of subjects: 18858
Study 19181729 — intervention group
Group type: EXPERIMENTAL
Intervention: Localities not participating in the trial
Number of subjects: 18858
Study 18175665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 30
Study 18175665 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 30
Study 18175665 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 30
Study 15023106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-determined leaflet
Number of subjects: 225
Study 15023106 — intervention group
Group type: COMPARATOR
Intervention: Routine pre-operative information (Control)
Number of subjects: 225
Study 15023106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative interview by a trained nurse
Number of subjects: 225
Study 11453445 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory (auditory‐tactile‐visual‐vestibular) intervention
Number of subjects: 37
Study 11453445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 9669812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole in addition to standard prophylaxis (oral co‐trimoxazol, colistin sulphate, and amphotericin B suspension)
Number of subjects: 68
Study 9669812 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis only (oral co‐trimoxazol, colistin sulphate, and amphotericin B suspension)
Number of subjects: 68
Study 7846918 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 100
Study 7846918 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 100
Study 3348155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dannon yogurt
Number of subjects: 8
Study 3348155 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal Maid yogurt
Number of subjects: 8
Study 3348155 — intervention group
Group type: COMPARATOR
Intervention: Borden yogurt
Number of subjects: 8
Study 31805311 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 0
Study 30447012 — intervention group
Group type: EXPERIMENTAL
Intervention: Online serious game for dental treatment preparation
Number of subjects: 60
Study 28205033 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 200
Study 28205033 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 200
Study 26480199 — intervention group
Group type: EXPERIMENTAL
Intervention: CB group
Number of subjects: 631
Study 26480199 — intervention group
Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 631
Study 26480199 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 631
Study 23320444 — intervention group
Group type: EXPERIMENTAL
Intervention: To-be-remembered words
Number of subjects: 0
Study 23320444 — intervention group
Group type: EXPERIMENTAL
Intervention: To-be-forgotten words
Number of subjects: 0
Study 20945066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 115
Study 20945066 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 115
Study 20945066 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 115
Study 19114188 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-potassium adenosine-lidocaine (MPAL) group (K(+), 10 mmol/L; adenosine, 0.7 mmol/L; lidocaine, 0.7 mmol/L)
Number of subjects: 134
Study 19114188 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-potassium adenosine-lidocaine (MPAL) group
Number of subjects: 134
Study 19114188 — intervention group
Group type: COMPARATOR
Intervention: High-potassium (HP) group (K(+), 20 mmol/L)
Number of subjects: 134
Study 19114188 — intervention group
Group type: COMPARATOR
Intervention: High-potassium adenosine-lidocaine (HPAL) group (K(+), 20 mmol/L; adenosine, 0.7 mmol/L; lidocaine, 0.7 mmol/L)
Number of subjects: 134
Study 16543907 — intervention group
Group type: EXPERIMENTAL
Intervention: GW660511X 200 mg
Number of subjects: 123
Study 16543907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 12941708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily for 3 months)
Number of subjects: 136
Study 12941708 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 136
Study 11326696 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan alone
Number of subjects: 17
Study 11326696 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan in combination with oxaliplatin and high dose 5-FU/FA
Number of subjects: 17
Study 8653990 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg tablet)
Number of subjects: 26
Study 8653990 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 26
Study 8653990 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine and terfenadine coadministration
Number of subjects: 26
Study 8653990 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine placebo
Number of subjects: 26
Study 1451313 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (PI)
Number of subjects: 12
Study 1451313 — intervention group
Group type: EXPERIMENTAL
Intervention: standardized 10% povidone-iodine (SPI)
Number of subjects: 12
Study 1451313 — intervention group
Group type: EXPERIMENTAL
Intervention: reformulated standardized 10% povidone-iodine (RSPI)
Number of subjects: 12
Study 6374681 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone administered as a single dose at night
Number of subjects: 146
Study 6374681 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone administered as divided doses twice daily
Number of subjects: 146
Study 6374681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (single dose at night and divided doses)
Number of subjects: 146
Study 31708330 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 147
Study 31708330 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 147
Study 31708330 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 147
Study 31708330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study 29146196 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based splint thickness in subgroup IB (disk displacement with reduction)
Number of subjects: 162
Study 29146196 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based splint thickness in subgroup IIB (disk displacement without reduction)
Number of subjects: 162
Study 29146196 — intervention group
Group type: COMPARATOR
Intervention: 3-mm-thick splints in subgroup IA (disk displacement with reduction)
Number of subjects: 162
Study 29146196 — intervention group
Group type: COMPARATOR
Intervention: 3-mm-thick splints in subgroup IIA (disk displacement without reduction)
Number of subjects: 162
Study 27050245 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 12
Study 24594552 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin, a recombinant form of human relaxin‐2
Number of subjects: 1161
Study 24594552 — intervention group
Group type: COMPARATOR
Intervention: Non-RELAX‐AHF‐type patients
Number of subjects: 1161
Study 22001114 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Number of subjects: 0
Study 22001114 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea (Glipizide) + Metformin
Number of subjects: 0
Study 19875266 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional face-to-face counseling about child's fasting
Number of subjects: 124
Study 19875266 — intervention group
Group type: COMPARATOR
Intervention: Current information without face-to-face counseling
Number of subjects: 124
Study 18047611 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen cryosurgery alone
Number of subjects: 21
Study 18047611 — intervention group
Group type: COMPARATOR
Intervention: Combination of liquid nitrogen cryosurgery and intralesional triamcinolone acetonide
Number of subjects: 21
Study 15025908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational belief that disagreement is not destructive
Number of subjects: 150
Study 15025908 — intervention group
Group type: COMPARATOR
Intervention: Irrational belief that disagreement is destructive
Number of subjects: 150
Study 15025908 — intervention group
Group type: COMPARATOR
Intervention: Control condition (counter-demand instructions)
Number of subjects: 150
Study 11424462 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation by propofol (Group P)
Number of subjects: 28
Study 11424462 — intervention group
Group type: COMPARATOR
Intervention: No sedation (Group C)
Number of subjects: 28
Study 9731006 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (mean serum level: 9.9 +/- 1.1 mg/L, Days 1 to 40) + inhaled salmeterol (50 microgram twice daily, Days 8 to 36)
Number of subjects: 25
Study 9731006 — intervention group
Group type: COMPARATOR
Intervention: Placebo + inhaled salmeterol (50 microgram twice daily, Days 8 to 36)
Number of subjects: 25
Study 8067245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline administered with a nasal bellows (OXBE)
Number of subjects: 121
Study 8067245 — intervention group
Group type: COMPARATOR
Intervention: Placebo bellows (PLBE)
Number of subjects: 121
Study 8067245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline with conventional nasal spray (OXSP)
Number of subjects: 121
Study 8067245 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (PLSP)
Number of subjects: 121
Study 2493760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 68
Study 2493760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 31486407 — intervention group
Group type: EXPERIMENTAL
Intervention: MotiMate app (full version)
Number of subjects: 88
Study 31486407 — intervention group
Group type: COMPARATOR
Intervention: Control app (monitoring only)
Number of subjects: 88
Study 28711476 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 15
Study 28711476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27325390 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Pump glucagon 0.3 µg/kg
Number of subjects: 19
Study 27325390 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Pump glucagon 1.2 µg/kg
Number of subjects: 19
Study 27325390 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Pump glucagon 2.0 µg/kg
Number of subjects: 19
Study 27325390 — intervention group
Group type: COMPARATOR
Intervention: GlucaGen 2.0 µg/kg
Number of subjects: 19
Study 27325390 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Pump glucagon
Number of subjects: 19
Study 24534400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone 400 μg twice daily for 10 days
Number of subjects: 525
Study 24534400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 24534400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone 400 μg
Number of subjects: 525
Study 24534400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 525
Study 22076554 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling during a 12 months intervention
Number of subjects: 0
Study 22076554 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling
Number of subjects: 0
Study 20308971 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit-High Intensity Group (CHG)
Number of subjects: 40
Study 20308971 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit-Low Intensity Group (CLG)
Number of subjects: 40
Study 20308971 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Group (EG)
Number of subjects: 40
Study 20308971 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 17549472 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL plus interleukin-2 (IL-2) for 2 months
Number of subjects: 88
Study 17549472 — intervention group
Group type: COMPARATOR
Intervention: IL-2 only
Number of subjects: 88
Study 15995044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic myelogenous leukemia (CML) in children and adolescents
Number of subjects: 40
Study 15995044 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms related to splenomegaly
Number of subjects: 40
Study 15995044 — intervention group
Group type: EXPERIMENTAL
Intervention: b3a2 transcript presence
Number of subjects: 40
Study 12518668 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (5 mg/day) followed by tamsulosin (0.4 mg/day)
Number of subjects: 60
Study 12518668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/day) followed by terazosin (5 mg/day)
Number of subjects: 60
Study 12518668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over treatment (terazosin followed by tamsulosin and vice versa)
Number of subjects: 60
Study 10432468 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg D-cycloserine
Number of subjects: 0
Study 10432468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7484574 — intervention group
Group type: EXPERIMENTAL
Intervention: Globular enhancement on single-pass, contrast-enhanced CT scans
Number of subjects: 50
Study 7484574 — intervention group
Group type: EXPERIMENTAL
Intervention: Globular enhancement isodense relative to that of the aorta
Number of subjects: 50
Study 7484574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonglobular enhancement in metastases
Number of subjects: 50
Study 7484574 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic categorization of lesions
Number of subjects: 50
Study 7484574 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement in identification of globular enhancement
Number of subjects: 50
Study 7484574 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement in categorization of lesions
Number of subjects: 50
Study 2147836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (D)
Number of subjects: 40
Study 2147836 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (E)
Number of subjects: 40
Study 7352483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous oxytocin
Number of subjects: 50
Study 7352483 — intervention group
Group type: COMPARATOR
Intervention: Low-dose prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 50
Study 30069590 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyaxial locking plate system
Number of subjects: 40
Study 30069590 — intervention group
Group type: COMPARATOR
Intervention: Monoaxial locking plate system
Number of subjects: 40
Study 28855452 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 413
Study 28855452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 25943350 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative docetaxel-5FU regimen (D 85 mg/m2, day 1 and 5FU 750 mg/m2/day continuous infusion, days 1-5 every 3 weeks) after preoperative dose-intense epirubicin-cyclophosphamide (E 150 mg/m2 and C 4000 mg/m2 every 3 weeks) and locoregional treatment.
Number of subjects: 174
Study 25943350 — intervention group
Group type: COMPARATOR
Intervention: Preoperative dose-intense epirubicin-cyclophosphamide (E 150 mg/m2 and C 4000 mg/m2 every 3 weeks) followed by mastectomy and radiotherapy.
Number of subjects: 174
Study 24313906 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise training (3 times per week for 12 weeks)
Number of subjects: 93
Study 24313906 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 93
Study 24313906 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise training
Number of subjects: 93
Study 22266683 — intervention group
Group type: EXPERIMENTAL
Intervention: Footrot vaccine (Footvax, MSD) plus targeted antibiotic therapy (long‐acting amoxicillin, Betamox LA, Norbrook Pharmaceuticals)
Number of subjects: 748
Study 22266683 — intervention group
Group type: COMPARATOR
Intervention: Targeted antibiotic therapy only
Number of subjects: 748
Study 19514186 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-tranquilizing and menstruation-regulating acupuncture method
Number of subjects: 40
Study 19514186 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture method
Number of subjects: 40
Study 17804322 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 1 W
Number of subjects: 60
Study 17804322 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 1.5 W
Number of subjects: 60
Study 17804322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser at 1 W
Number of subjects: 60
Study 17804322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser at 1.5 W
Number of subjects: 60
Study 17804322 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Nd:YAG laser to Er,Cr:YSGG laser
Number of subjects: 60
Study 15180967 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise intervention using a flywheel ergometer (FWE) during bed rest.
Number of subjects: 0
Study 15180967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention).
Number of subjects: 0
Study 15180967 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise intervention using a flywheel ergometer (FWE).
Number of subjects: 0
Study 12491697 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil tablet 25 mg, p.o., qn for 42 days
Number of subjects: 80
Study 12491697 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg, p.o., qn for 42 days
Number of subjects: 80
Study 9535521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral translations
Number of subjects: 0
Study 9535521 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior/posterior translations
Number of subjects: 0
Study 9535521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lateral and anterior/posterior translations
Number of subjects: 0
Study 7630674 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg up to 60 mg)
Number of subjects: 86
Study 7630674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 2621763 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 18
Study 2621763 — intervention group
Group type: COMPARATOR
Intervention: No stress management training (control)
Number of subjects: 18
Study 31968177 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH My Breath program
Number of subjects: 12
Study 31968177 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 12